Tamoxifen and Uterine Disease Risk in Young Breast Cancer Survivors: Evidence from a Target Trial Emulation Study

Highlights

• Tamoxifen use in premenopausal women (aged 20-50) is associated with a 4.2-fold increased risk of endometrial cancer in per-protocol analyses.
• The risk for benign but clinically significant uterine diseases, such as endometrial polyps and hyperplasia, is elevated four- to eight-fold.
• Uterine disease risk exhibits a clear duration-dependent relationship, emphasizing the need for long-term surveillance.
• This study provides critical evidence for the Asian population, where data on young tamoxifen users was previously limited.

Background

Tamoxifen has served as a cornerstone of adjuvant endocrine therapy for estrogen receptor-positive (ER+) breast cancer for decades. While its efficacy in reducing recurrence and mortality is undisputed, its role as a selective estrogen receptor modulator (SERM) carries tissue-specific risks. In the breast, tamoxifen acts as an antagonist; however, in the uterus, it can exhibit agonistic properties. This pro-estrogenic effect on the endometrium has been well-documented in postmenopausal women, where it significantly increases the incidence of endometrial cancer.

In contrast, the risk profile for premenopausal women has been less clear. Previous studies often grouped pre- and postmenopausal patients or lacked sufficient power to isolate risks in younger cohorts. As the incidence of early-onset breast cancer rises, particularly in Asian regions such as Taiwan, understanding the uterine sequelae of tamoxifen in premenopausal patients is vital for clinical counseling and monitoring.

Key Content

Methodological Advances: The Target Trial Emulation

The primary evidence comes from a retrospective cohort study by Yeh et al. (2026), which utilized a target trial emulation framework to minimize the biases typically associated with observational data. Using the Taiwan National Health Insurance claims database linked to the cancer registry, the study analyzed 23,062 tamoxifen users and 3,000 nonusers between 2010 and 2019. The cohort consisted of women aged 20-50 years with ER+ breast cancer who had undergone definitive surgery (mastectomy or lumpectomy).

Evidence by Uterine Disease Subtype

The study differentiated between various uterine pathologies, providing a nuanced view of the drug’s impact on the reproductive tract:

• Endometrial Polyps: In the intention-to-treat (ITT) analysis, the hazard ratio (HR) was 4.15 (95% CI, 2.65–6.50). The per-protocol (PP) analysis showed an even stronger association with an HR of 4.75.
• Endometrial Hyperplasia: This precursor to malignancy showed the highest risk increase. The ITT HR was 5.42 (95% CI, 4.09–7.18), while the PP analysis revealed an HR of 8.37 (95% CI, 5.24–13.35).
• Endometrial Cancer: While the ITT HR was 2.41 and did not reach statistical significance (95% CI, 0.86–6.72), the per-protocol analysis—which more accurately reflects patients who remained on therapy—demonstrated a statistically significant risk of 4.20 (95% CI, 1.20–14.63).

Duration of Therapy and Cumulative Risk

A critical finding of the research was the duration-dependent risk. As tamoxifen treatment continued, the probability of developing any uterine disease increased. This is particularly relevant given that current guidelines often suggest 5 to 10 years of adjuvant therapy. The study highlights that the cumulative incidence of uterine pathologies continues to diverge between users and nonusers over time, necessitating vigilance throughout the treatment course.

Expert Commentary

The findings from this Taiwan-based cohort are pivotal for global oncology practice. The agonistic effect of tamoxifen in the premenopausal uterus appears more potent than some previous smaller studies suggested. From a biological perspective, the competitive inhibition of estrogen by tamoxifen in the breast does not prevent its stimulation of the endometrial lining in younger women, even in the presence of functioning ovaries.

Clinicians must balance the life-saving benefits of tamoxifen in preventing breast cancer recurrence against these uterine risks. While routine endometrial screening (such as transvaginal ultrasound) in asymptomatic premenopausal tamoxifen users is currently controversial and not broadly recommended by all guidelines due to high false-positive rates (especially regarding polyps), this data suggests that any abnormal uterine bleeding (AUB) in this population must be investigated aggressively. Furthermore, for patients at high risk for uterine diseases, the use of Aromatase Inhibitors (AI) plus Ovarian Function Suppression (OFS) may be considered as an alternative, though this comes with its own set of side effects, such as bone density loss.

Conclusion

Adjuvant tamoxifen therapy in women of premenopausal age is associated with a significantly higher risk of endometrial polyps, hyperplasia, and cancer. The risk is notably higher in those with longer treatment durations. These findings underscore the importance of integrating gynecological monitoring into the survivorship care plans for young breast cancer patients. Future research should focus on identifying biomarkers that can predict which young women are most susceptible to tamoxifen-induced uterine changes, as well as evaluating the long-term safety of alternative endocrine therapies in this demographic.

References

• Yeh YC, Chen PC, Huang HY, Chang CY. Tamoxifen Use and Risk of Uterine Diseases in Young Women With Breast Cancer. Obstetrics and gynecology. 2026-03-05. PMID: 41785462.